Dec-05 -
Genito-Urinary Group
EORTC 30924 – Randomized phase II / III study of high dose intensity M-VAC chemotherapy + G-CSF versus classic M-VAC in advanced urothelial tract tumors.
After a seven-year follow up in patients with advanced urothelial tract cancer, EORTC found that high-dose of the chemotherapy combination (MVAC + G-CSF), provided higher response rates and decreased toxicity in these patients. This became the standard of care.
